BioSpace News Archive

Ethos Medical, a startup founded by Georgia Tech engineering alumni, was recently awarded a $225,000 grant from the National Science Foundation’s Small Business Innovation Research program.

With the surging demand for sample collection kits for diagnosing COVID-19 and other upper respiratory tract pathogens, COPAN is concentrating its efforts on strategic items to maximize product output and supply during the ongoing surge in demand due to the novel Coronavirus outbreak.

Spero Therapeutics, Inc. announced that on February 28, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 24,500 shares of its common stock to two new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, or the 2019 Inducement Plan.

GlaxoSmithKline (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Advil Dual Action with Acetaminophen as an over-the-counter (OTC) product for pain relief.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on February 28, 2020 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to fourteen individuals hired by Sarepta in February 2020.

Nektar Therapeutics’ senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time..

As part of its mission to promote the prevention and treatment of cardiovascular disease, including stroke, in Blacks and other minorities, the Association of Black Cardiologists is pleased to announce our commitment to the National Hypertension Control Roundtable® as a founding member.

Harbour BioMed (HBM) today announced U.S. Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to begin clinical studies with HBM4003, its next generation anti-CTLA-4 antibody for the treatment of cancer.

Verastem, Inc. (NASDAQ: VSTM) (the “Company”), today announced that it has agreed to sell approximately 46.5 million shares of its common stock to certain institutional investors, including RA Capital Management, Vivo Capital, Venrock Healthcare Capital Partners, Farallon Capital Management, Acuta Capital, EcoR1 Capital LLC, Avidity Partners and Logos Capital.,

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that the Kitakyushu General Hospital, a hospital in southwestern Japan, completed its first surgical procedures using the Senhance® Surgical System